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Background
Chronic obstructive lung disease (COPD) is characterized
by a not fully reversible and usually progressive airflow
limitation. The disease is associated with an inflammatory
response of the lungs to noxious particles, mainly cigarette
smoke but also alpha 1-antitrypsin (AAT) deficiency
predisposes to COPD. The usual clinical practice for
diagnosing COPD is following symptoms, performing lung
function and the assessment of responses to inhaled
pharmacological agents. These tests have been standardized
and are generally considered as informative [1]. The tests
are time consuming. Still the quality of the tests is
influenced by experience and may differ depending where
the tests are performed. Further, it is suggested that every
COPD patient is once screened for AAT deficiency
(AATD). Alpha 1-antitrypsin deficiency is a co-dominant
inherited disorder that is diagnosed by low serum levels,
genotyping and phenotyping of AAT.
Usually the serum AAT levels are analyzed first. If the
serum levels are decreased further procedures like genotyp-
ing (with polymerase chain reaction) and phenotyping
(isoelectric focusing) are suggested. The costs of these
diagnostic procedures are high [2] and therefore often not
carried out. Thus, there is a need for novel diagnostic
methods that are simple, fast and cost-effective and maybe
performed bedside. Within the past decade, cellular and
molecular techniques have been utilized as options for the
diagnosis and monitoring of COPD and AAT deficiency [3].
The analysis of exhaled breath (EB) has been used to
noninvasively obtain information about inflammatory pro-
cesses within the lung. EB contains a complex mixture of
volatile organic compounds (VOCs), which can be detected
using gas chromatography–mass spectrometry (GC-MS)
[4]. Electronic noses (eNoses) use a concept essentially
different from GC-MS. In addition, they allow the online
recognition of complex VOC mixtures via composite
nanosensor arrays in combination with learning algorithms
[5, 6]. Another approach is the ion mobility spectroscopy
(IMS), were about 10 ml human breath will be analyzed
directly and without any pre-enrichment. Two different
types of IMS, such coupled to multi-capillary columns
(MCC/IMS) [7–15] and differential mobility spectrometers
[16, 17] were used.
It is currently assumed that COPD with or without AAT
deficiency shows different molecular and cellular character-
istics due to the pathophysiological inflammation present in
AAT deficiency [18]. Thus, it may be that the VOC profile
or smellprint is different in the EB of patients with COPD
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with and without AAT deficiency. Based on this possibility,
it was the aim of our study to compare smellprints between
COPD patients with confirmed AAT deficiency and COPD
patients without AAT deficiency. In another approach also
the influence of AAT augmentation therapy should be
studied. Patients with severe AATD can be treated with
weekly AAT infusions (60 mg/kg body weight). This
therapy regimen is based on studies showing an increase
of AAT lung levels as well as an increase of the
antineutrophil elastase capacity in the epithelial lining fluid
of the lung [1]. Considering this, an influence of the
augmentation on the smellprint of AATD patients seems
Parameter Value
Ionization source 63Ni (555 MBq)
Electric field strength 320 V/cm
Length of drift region 12 cm
Diameter of drift region 15 mm
Length of ionization chamber 15 mm
Shutter opening time 300 μs
Shutter impulse time 100 ms
Drift gas synthetic air (20.5 % O2 (4.5), 79.5 % N2 (5.0))
Drift gas flow 100 ml/min to 300 ml/min
Pressure 101 kPa (ambient pressure)
Multi-capillary column OV-5, polar
Column temperature 40 °C





Fig. 1 IMS chromatograms
before and after AATD
augmentation
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reasonable. Hence, the second aim of the study was to
detect the influence of intravenously given AAT on the
composition of VOCs in EB of AATD patients.
Patients
We included patients with genetically proved severe AATD
(PiZZ genotype). All patients were fasting for at least 2 h.
Patients had to wash out their mouth with water. For
sampling the patients breathed into the device. For every
breath the first expiratory 40 ml were discarded to exclude air
of the oral cavity. The patients breathed until 10 ml of
expiratory air (excluding the oral cavity) were obtained by the
device for sampling. From AATD patients breath samples
were taken twice, directly before and 2 h past their infusion or
augmentation. The numbers of breath samples includedwithin
the two different cases investigated are:
& Before and after substitution: 2
& COPD without AATD: 8
& COPD based on AATD: 17.
Method
The IMS coupled to a multi-capillary column (MCC/IMS)
used was a BioScout (B&S Analytik, Dortmund, Germany)
consisting of the MCC/IMS and a SpiroScout (Ganhorn
Medizin Electronic, Niederlauer, Germany) as sample inlet
unit. The major parameters are summarized elsewhere [8–
12, 19–23]. In this spectrometer a 550 MBq 63Ni β-
radiation source was applied for the ionization of the carrier
gas (air). It was connected to a polar multi-capillary column
(MCC, type OV-5, Multichrom Ltd, Novosibirsk, Russia)
used as the pre-separation unit. In this MCC the analytes
of exhaled breath were sent through 1000 parallel
capillaries, each with an inner diameter of 40 μm and a
film thickness of 200 nm. The total diameter of the
separation column was 3 mm. The relevant MCC parameters
are listed in Table 1.
All subjects were requested to exhale through a
mouth piece connected to a Teflon tube. In each case
end-tidal breath, controlled by a flow sensor, was
collected in a sample loop of 10 ml volume. The

















Fig. 2 Box-and-whisker plots
related to increasing and de-
creasing signals, before and after
AATD augmentation
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# Area Norm U 1/K0 VS/cm
2 RT/s Nearest analyte
1 P_01 0.000 0.579 1.7 Butanole
2 P_02 0.000 0.550 2.3 Acetone
3 P_07 0.000 0.584 6.0 2-Hexanone
4 P_09 0.000 0.607 6.3 1-Pentanole
5 P_10 0.000 0.569 6.3 1-Butanole
6 P_11 0.000 0.531 6.2 2-Butanone
7 P_12 0.000 0.532 8.6 2-Propanole
8 P_13 0.000 0.578 8.1 2-Hexanone
9 P_14 0.000 0.550 8.6 3-Pentanone
10 P_18 0.000 0.562 17.0 2,5-Dimethylpyrazine
11 P_22 0.000 0.581 23.0 1,2,4-Trimethylbenzene
12 P_28 0.000 1.073 29.4 unknown
13 P_41 0.000 0.608 45.8 unknown
14 P_42 0.000 0.641 51.7 unknown
15 P_44 0.000 0.576 55.6 1,2-Butandiole
16 P_50 0.000 0.598 73.6 unknown
17 P_54 0.000 0.664 77.4 Menthon
18 P_56 0.000 0.735 77.7 unknown
19 P_60 0.000 0.668 84.4 unknown
20 P_62 0.000 0.607 88.5 unknown
21 P_64 0.000 0.616 96.9 unknown
22 P_65 0.000 0.760 95.4 unknown
Table 2 Position of the signals
discriminating AATD before
and after augmentation
Fig. 3 Signals of potential relevance to AATD within the IMS chromatogram
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capillary column for a first chromatographic separation
after reaching 3 times 10ml above the dead volume. Using the
software VOCan 1.4 (B&S Analytik, Dortmund, Germany)
the dead volume was adjustable and fixed in the present case
to 500 ml. The expiration was controlled by a CO2 sensor
element integrated in the SpiroScout and recorded for each
subject.
The peaks were characterized using the software Visual
Now 2.2 (B&S Analytik, Dortmund, Germany), which is
described elsewhere [8, 24–27]. All peaks found are
characterized by their position with drift time (corresponding
1/K0-value), retention time and their concentration repre-
sented by the peak height. For both groups and each of the
peaks a box-and-whisker plot was realized.
A preliminary relation between the peak position and the
identity of the analyte was obtained using the database
BSIMSDB 1.4 (B&S Analytik, Dortmund, Germany), but
parallel measurements using e.g. GC/MSD (gas chroma-
tography/mass selective detector) should be realized with
respect of further confirmation.
Results
We compare two different cases
& IMS chromatograms before and after substitution
& AATD and COPD (without AATD), here we describe
differences between COPD without AATD and COPD
based on AATD.
The IMS chromatograms before and after AAT augmenta-
tion are compared in Fig. 1. The signal with the highest rank
sum is marked by black rectangles. The box-and-whisker
plots related to increasing and decreasing signals, before and
after AAT augmentation are shown in Fig. 2. Totally, 22
different signals were found with rank sum 0.00, the best
value. The positions were reported in Table 2 and shown in
Fig. 3. It should be noted, that because of the preliminary
status of the study and the rather low number of subjects
included so far, the findings need confirmation within a larger
group, but should encourage investigations of exhaled breath
to identify potential biomarkers.
AATD
COPD without AATD
Fig. 4 Signals of AATD and
COPD without AATD within
IMS chromatograms
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Furthermore, the signals P_10, P_11, P_12 and P_13
should be considered also in relation to case two, dealing
with the difference between COPD without AATD and
COPD based on AATD.
Typical IMS chromatograms for case two are shown in
Fig. 4. Some peaks useful for discrimination between
COPD with and without AATD are marked. The box-and-
whisker plots for the five signals with the lowest rank sum
with respect to a potential separation between the two
groups investigated are shown in Fig. 5 and described in
Table 3. In nearly all cases the signal within the group of
COPD without AATD is higher than in AATD.
In the group of COPDwith and without AATD the numbers
of patients were higher than in case before and after
substitution. Therefore, in Table 4 the values of accuracy,
sensitivity, specificity and the positive and negative predictive
value are shown for the five peaks with the rank sum less
than 0.2. In addition, the best thresholds calculated on the
peak height scale are shown. The accuracy is in all cases
higher than 75 %. For peak P_72 the sensitivity was 100 %,




































































































Fig. 5 Box-and-whisker plots
of signals potentially separating
AATD and COPD without
AATD
Table 3 Position of the signals discriminating AATD and COPD
without AATD
# Area Norm U 1/K0 VS/cm
2 RT/s Nearest analyte
1 P_72 0.169 0.627 208.1 unknown
2 P_10 0.176 0.569 6.3 1-Butanole
3 P_11 0.184 0.531 6.2 2-Butanone
4 P_12 0.191 0.532 8.6 2-Propanole
5 P_13 0.199 0.578 8.1 2-Hexanone
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to be promising for a preliminary study with just 25 cases.
Generally, the finding needs further confirmation and a higher
number of subjects should be included within the study.
Conclusions
Two different case studies were investigated using MCC/
IMS: before and after AAT substitution and COPD with and
without AATD. For the first case, from two patients, 22
different signals were found with rank sum 0.00, the best
value to differentiate. In case two, the 17 samples with
AATD and eight with COPD without AATD could be
separated by five peaks.
Our preliminary results demonstrate, that distinct
patterns of a small number of IMS peaks are found to
be useful to separate the classes under investigation.
Therefore, MCC/IMS seems to be a promising method
for the noninvasive identification as shown before for
lung cancer and sarcoidosis patients [19]. But, because of
the comparatively low number of subjects included in the
preliminary study, a higher number should be investigated.
In addition, the relations of the peaks to the analyte need
further confirmation, e.g. using parallel measurements
using GC/MSD.
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